Concepedia

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate

Bruno Émond, Kruti Joshi, Antoine C. El Khoury, Marie‐Hélène Lafeuille, Dominic Pilon, Neeta Tandon, Hela Romdhani, Patrick Lefèbvre

PharmacoEconomics - Open · 2018 · 18 citations · 19 references

DOIFull text

Open access

References

19

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Jeffrey A. Lieberman, T. Scott Stroup, Joseph P. McEvoy et al. · New England Journal of Medicine · 2005 · 5.9K citations · Full text

The Economic Burden of Schizophrenia in the United States in 2002

Eric Q. Wu, Howard G. Birnbaum, Lizheng Shi et al. · The Journal of Clinical Psychiatry · 2005 · 612 citations

The Economic Burden of Schizophrenia in the United States in 2013

Martin Cloutier, Myrlene Sanon Aigbogun, Annie Guérin et al. · The Journal of Clinical Psychiatry · 2016 · 481 citations

Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge

Steven C. Marcus, Jacqueline Zummo, Amy R. Pettit et al. · Journal of Managed Care & Specialty Pharmacy · 2015 · 241 citations · Full text

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

Joris Berwaerts, Yanning Liu, Srihari Gopal et al. · JAMA Psychiatry · 2015 · 193 citations